Ascendis Pharma Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Ascendis Pharma Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 |
|---|---|---|---|---|---|---|---|
| operating activities | |||||||
| net profit/(loss) for the period | -131,035 | ||||||
| reversal of finance income | -3,575 | 33,128 | 3,389 | -35,239 | -45,135 | 21,616 | 10,374 |
| reversal of finance expenses | 77,161 | 8,425 | 16,988 | 8,812 | 9,840 | 25,106 | 10,548 |
| reversal of (gain)/loss on disposal of property, plant and equipment | -91 | ||||||
| reversal of income taxes | 2,508 | 5,790 | 645 | -429 | 1,297 | ||
| adjustments for non-cash items: | |||||||
| non-cash consideration relating to revenue | -24,770 | -580 | -571 | -589 | -614 | -634 | -638 |
| share of profit/(loss) of associates | 5,796 | ||||||
| share-based payment | 17,281 | 15,908 | 17,184 | 19,880 | 13,688 | 13,873 | 13,537 |
| depreciation | 4,359 | 4,827 | 4,632 | 4,534 | 4,435 | 4,526 | 4,404 |
| amortization | 118 | 150 | 111 | 111 | 111 | 111 | 111 |
| changes in working capital: | |||||||
| inventories | -23,750 | -19,799 | -21,213 | -17,068 | -20,178 | -26,697 | -2,654 |
| receivables | -11,286 | -8,523 | -13,535 | -1,107 | -9,608 | -5,457 | -376 |
| prepayments | -3,904 | -5,175 | 6,541 | -2,603 | -10,176 | 2,460 | 768 |
| contract liabilities | -950 | 2,153 | -115 | -8,862 | -256 | -2,079 | 12,592 |
| trade payables, accrued expenses and other payables | -19,025 | -10,053 | 4,288 | -4,920 | 14,236 | 23,415 | 14,568 |
| increase/(decrease) in provisions | 7,076 | ||||||
| cash flows generated from/(used in) operations | -104,087 | ||||||
| finance income received | 3,588 | 4,471 | 4,174 | 4,524 | 3,879 | 1,463 | 2,980 |
| finance expenses paid | -877 | -7,040 | -886 | -6,840 | -906 | -7,268 | -784 |
| income taxes received/ | -206 | ||||||
| cash flows from/(used in) operating activities | -101,582 | ||||||
| investing activities | |||||||
| acquisition of property, plant and equipment | -199 | 63 | -976 | -444 | -1,085 | -3,782 | -3,163 |
| settlement of marketable securities | 7,354 | 6,583 | 23,150 | 47,401 | 211,731 | 55,988 | 88,401 |
| cash flows from/(used in) investing activities | 7,155 | ||||||
| financing activities | |||||||
| repayment of borrowings | -2,786 | ||||||
| proceeds from exercise of warrants | 21,209 | 2,018 | 6,194 | 208 | 1,866 | 3,130 | 1,337 |
| cash flows from/(used in) financing activities | 18,423 | ||||||
| increase/(decrease) in cash and cash equivalents | -76,004 | ||||||
| cash and cash equivalents at january 1 | 392,164 | 0 | 0 | 0 | 444,767 | 0 | 0 |
| effect of exchange rate changes on balances held in foreign currencies | 4,079 | -7,230 | 6,187 | 1,421 | -6,386 | -22,430 | 20,753 |
| cash and cash equivalents at march 31 | 320,239 | 501,281 | |||||
| cash and cash equivalents include: | |||||||
| bank deposits | 320,239 | -49,104 | 47,046 | -107,059 | 501,281 | -176,208 | -66,226 |
| net profit/(loss) for the year | |||||||
| reversal of gain and loss on disposal of property, plant and equipment | 0 | 21 | 0 | 8 | |||
| share of profit/(loss) of associate | |||||||
| impairment of property, plant and equipment | |||||||
| investment in associate | |||||||
| proceeds from disposal of property, plant and equipment | 5 | ||||||
| reimbursement for acquisition of property, plant and equipment | |||||||
| development expenditures | |||||||
| purchase of marketable securities | -53,003 | -71,139 | |||||
| payment of principal portion of lease liabilities | -2,735 | -2,618 | -2,517 | -2,568 | -1,779 | -1,414 | |
| net proceeds from borrowings | -3,526 | ||||||
| net proceeds from follow-on public offerings | |||||||
| acquisitions of treasury shares, net of transactions costs | |||||||
| payment of withholding taxes under stock incentive programs | |||||||
| cash and cash equivalents at december 31 | |||||||
| short-term marketable securities | 12,645 | 2,169 | |||||
| net profit / (loss) for the period | -162,223 | -121,432 | -110,914 | -168,958 | |||
| increase / (decrease) in provisions | 9,469 | 1,642 | 1,983 | 1,425 | |||
| share of profit / (loss) of associate | 6,794 | 7,450 | 1,227 | 3,697 | |||
| cash flows generated from / (used in) operations | -127,637 | -149,820 | -150,043 | -100,761 | |||
| income taxes received / | -370 | -992 | 26 | -268 | |||
| cash flows from / (used in) operating activities | -124,719 | -153,128 | -147,044 | -98,833 | |||
| reimbursement from acquisition of property, plant and equipment | 0 | ||||||
| cash flows from / (used in) investing activities | 22,220 | 46,957 | 210,646 | 14,099 | |||
| acquisition of treasury shares, net of transaction costs | 1 | ||||||
| cash flows from / (used in) financing activities | 143,358 | -2,309 | -702 | -76 | |||
| increase / (decrease) in cash and cash equivalents | 40,859 | -108,480 | 62,900 | -84,810 | |||
| cash and cash equivalents at september 30 | |||||||
| net proceeds from convertible senior notes | 0 | 0 | |||||
| cash and cash equivalents at june 30 | |||||||
| reversal of tax charge | 5,349 | -167 | |||||
| net increase in cash and cash equivalents | |||||||
| cash flows from / used in investing activities | |||||||
| b. |
We provide you with 20 years of cash flow statements for Ascendis Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ascendis Pharma stock. Explore the full financial landscape of Ascendis Pharma stock with our expertly curated income statements.
The information provided in this report about Ascendis Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.